Catalist-listed metal-stamping firm CFM Holdings has on June 3 entered into a sale and purchase agreement (SPA) to acquire 51% of the issued share capital in  SING-SWE MM Biotechnology, a distributor of Covid-19 testing kits.

Have a premium account? Sign in to continue reading.

Unlimited access to all stories from $99.9/year*

The latest reporting and analysis from business and investments to news and views on social issues.


  • Simultaneous logins across all devices
  • Instant access to past digital issues
  • Unlimited access to The Edge Malaysia
  • *For annual subscription plan only. T&Cs apply